Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aripiprazole - Bristol-Myers Squibb/Otsuka Pharmaceutical

Drug Profile

Aripiprazole - Bristol-Myers Squibb/Otsuka Pharmaceutical

Alternative Names: Abilify; ABILIFY MAINTENA; Abilify Maintena; Abilify MyCite; ABILIFY MYCITE; Abilitat; Ao Pai; Aripiprazole depot - Otsuka Pharmaceutical/Lundbeck; Aripiprazole ECER tablets; Arlemide; OPC-14597; OPC-14597 IMD; OPC-31

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Bristol-Myers Squibb; Indiana University; Lundbeck A/S; Otsuka Pharmaceutical
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D2 receptor partial agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor partial agonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autistic disorder; Bipolar disorders; Gilles de la Tourette's syndrome; Major depressive disorder; Schizophrenia
  • Phase III Agitation; Pervasive child development disorders
  • Discontinued Attention-deficit hyperactivity disorder; Psychotic disorders

Most Recent Events

  • 31 Mar 2021 Preregistration for Schizophrenia in China (IM) before March 2021
  • 03 Mar 2021 Health Canada issues a Notice of Compliance for an alternative initiation regimen for aripiprazole in Schizophrenia and Bipolar disorders
  • 24 Dec 2020 Otsuka Beijing Research Institute completes a phase III trial in Autistic disorder (In Children, In Adolescents) in China (NCT03487770)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top